肝脏疾病患者血浆中组织因子途径抑制物与抗凝血酶的表达  

Expression of Tissue Factor Pathway Inhibitor and Antithrombin in Patients with Hepatic Disease

作　　者：刘敏涓[1] 周立红[1] 刘卉[1] 董临江 

机构地区：[1]广州医学院附属二院,广州510260 [2]深圳宝安医院,深圳518101

出　　处：《血栓与止血学》2005年第4期159-161,共3页Chinese Journal of Thrombosis and Hemostasis

基　　金：广东省医学科研课题(A 2003317)

摘　　要：目的研究肝脏疾病患者血浆中组织因子途径抑制物(TFPI)与抗凝血酶(AT)的改变及其临床意义。方法 TFPI抗原(TFPI：Ag)采用双夹心ELISA抗原测定法。TFPI活性(TFPI：A)采用发色底物法。AT：Ag采用免疫浊度法。AT：A采用发色底物法。结果急性中毒性肝炎14例,急性病毒性肝炎20例,慢性乙型肝炎48例,肝硬化50例,共132例肝病患者：TFPI：Ag与TFPI：A均高于正常值(P＜0.05,P＜0.01),仅失代偿期肝硬化TFPI：Ag降低(P＜0.05)。AT：Ag除失代偿期肝硬化外,均接正常值。AT：A除慢性乙肝与肝硬化低于正常值外,其他组接近正常值。结论肝病患者TFPI上调,表明组织受损与炎症存在,而AT正常或降低,表明肝细胞合成AT减少。而失代偿期肝硬化除TFPI：A保持高水平外,其余多项指标均降低,表明肝组织毁损严重,抗凝蛋白合成功能减退。Objective To investigate the chang of tissue factor pathway inhibitor （TFPI） and antithrombin （AT） in the plasma of patients with hepatic disease. Methods TFPI： Ag by ELISA assay. TFPI ： A by colored substrate method. AT： Ag by immune furbidimetry. AT： A by colored substrate method. Results The plasma level of TFPI ： Ag （ except for decompensatory phase of cirrhosis ） and TFPI： A all increased than control group. The level of AT： Ag（ except for decompensatory phase of cirrhosis ） all consistent with normol value. AT：A except for chronic hepaitis B and hepatocirrhosis lower than normol value , other groups close to control group. Conclusion The elevation of TFPI in hepatic inflammatory disease indication of tissue injury and inflammation . The lower level of AT are expression decreased of symtheic proteins in liver. Hepatocirrhosis on the part of syntheic proteins lower preforable to other hepatic disease.

关 键 词：肝脏疾病 组织因子途径抑制物 抗凝血酶 

分 类 号：R575.2[医药卫生—消化系统]